Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago.
Sanofi is one of several pharma companies that is on a quest to use digital health to make trials cheaper and more effective – and has found another partner to help it.
Sanofi’s is to pay back money to the Philippines government for unused doses of its Dengue fever vaccine, after serious safety concerns halted its use.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.